stockportfolio.pro
Odyssey Therapeutics, Inc. (ODTX)
Healthcare · Biotechnology · NasdaqCM
Odyssey Therapeutics, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $1.04M | $4.47M | $2.98M |
| Gross profit | — | — | — | — |
| Net income | $-124.67M | $-125.94M | $-129.32M | $-148.65M |
| Net margin | — | -12144.5% | -2891.8% | -4994.9% |
Source: Odyssey Therapeutics, Inc. SEC filings (10-K).
Explore 4 years of Odyssey Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ODTX in your portfolio →
Odyssey Therapeutics, Inc. financial history by metric
About Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Odyssey Therapeutics, Inc. — frequently asked questions
What is Odyssey Therapeutics, Inc.'s revenue?
Odyssey Therapeutics, Inc. (ODTX) reported revenue of $2.98M for fiscal year 2025, down 33.5% from the prior year, according to its SEC filings.
Is Odyssey Therapeutics, Inc. profitable?
No — ODTX reported a net loss of $-148.65M in fiscal 2025.
What is ODTX's P/E ratio?
Odyssey Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Odyssey Therapeutics, Inc. have?
As of fiscal year 2025, ODTX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Odyssey Therapeutics, Inc.'s market cap?
Odyssey Therapeutics, Inc. (ODTX) has a market capitalization of about $784.51M, based on the latest data in our nightly-refreshed cache.
When does Odyssey Therapeutics, Inc.'s fiscal year end?
ODTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Odyssey Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.